InSightec has announced it has received FDA approval for its ExAblate MRI guided focused ultrasound treatment of bone metastases in patients who are not candidates for or refuse to undergo radiation treatment, according to a news release.
The ExAblate system is designed to be exclusively compatible with GE Healthcare's normal and wide bore systems, including Signa HDxt 1.5T, Signa HDxt 3.0T, Optima MR450 & 450w and Discovery MR750 & 750w. It is designed to combine therapeutic acoustic ultrasound waves with continuous guidance and treatment monitoring by MRI.
"The FDA approval of ExAblate is an exciting next step in GE's investment in InSightec," said Tom Gentile, president and CEO of GE Healthcare Systems and InSightec board member, in the release. "Pain is the most common and most severe symptom for patient's suffering from bone cancer; we believe that ExAblate can help significantly improve the quality of life for patients. This is the first approved oncology application of ExAblate and we are excited that InSightec will continue researching in this area to expand the applications of this product."
InSightec is headquartered in Israel.
Related Articles on FDA Clearances:
Raiing Receives FDA Clearance for Wireless Thermometer
Cook Medical Receives FDA Approval for Drug-Eluting Stent
Quantel Medical Receives FDA Clearance for Ophthalmic Laser System